Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0601 for Hemophilia A or B with Inhibitors
NCT06289166Phase 2Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Mar 2024
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bemiltenase alfa in hemophilia A, hemophilia B (HB), sponsored by Staidson Biopharmaceutical. Started Mar 2024; status: completed.
02
Drugs
bemiltenase alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT06289166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289166.